

Amendments to the Claims:

Please enter the following amendments to the claims, with insertions indicated by underlining and deletions by strikethrough.

1-43. (Canceled)

44. (Withdrawn, currently amended) A method for treating medullary thyroid carcinoma comprising administering to a subject, either concurrently or sequentially, a therapeutically effective amount of at least one naked anti-CEA monoclonal antibody according to claim 113 and at least one apoptosis agent, and optionally formulated in a pharmaceutically acceptable vehicle, wherein the combination of naked anti-CEA MAb and therapeutic agent is more effective for treatment of medullary thyroid carcinoma than either naked anti-CEA MAb or therapeutic agent alone or the sum of the effects of naked anti-CEA MAb and therapeutic agent administered individually.

45-49. (Canceled)

50. (Withdrawn, currently amended) The method of claim ~~44~~49, wherein the framework regions (FRs) of the light and heavy chain variable regions of said naked humanized MN-14 antibody comprise at least one amino acid substituted from the corresponding FRs of a murine MN-14 monoclonal antibody.

51. (Withdrawn) The method of claim 50, wherein said naked humanized MN-14 antibody comprises at least one amino acid from said corresponding FR of said murine MN-14 light chain or heavy chain variable region.

52-110. (Canceled)

111. (Currently amended) A composition comprising:

a) a naked humanized MN-14 (hMN-14) antibody comprising light chain variable region CDR sequences CDR1 (KASQDVGTSVA, SEQ ID NO: 20); CDR2 (WTSTRHT, SEQ ID NO: 21); and CDR3 (QQYSLYRS, SEQ ID NO: 22); and heavy chain variable region CDR sequences CDR1 (TYWMS, SEQ ID NO: 23); CDR2 (EIHPDSSTINYAPSLKD, SEQ ID NO: 24); and CDR3 (LYFGFPWFAY, SEQ ID NO: 25) and human framework region sequences and an IgG1 human constant region, ~~wherein administration of the naked hMN-14 antibody to a cancer expressing CEA sensitizes the cancer to administration of an apoptosis agent;~~ and

b) an apoptosis agent selected from the group consisting of vincristine, doxorubicin, dacarbazine (DTIC), cyclophosphamide, CPT-11, oxaliplatin, 5-fluorouracil/leucovorin and gemcitabine, wherein the combination of the naked hMN-14 antibody and the apoptosis agent is more effective for treatment of human medullary thyroid carcinoma or human colorectal cancer than either the naked anti-CEA MAb or the apoptosis agent alone or the sum of the effects of the naked anti-CEA MAb and the apoptosis agent administered individually.

112. (canceled)

113. (Previously presented) A composition comprising:

a) a naked humanized MN-14 (hMN-14) antibody comprising light chain variable region CDR sequences CDR1 (KASQDVGTSVA, SEQ ID NO: 20); CDR2 (WTSTRHT, SEQ ID NO: 21); and CDR3 (QQYSLYRS, SEQ ID NO: 22); and heavy chain variable region CDR sequences CDR1 (TYWMS, SEQ ID NO: 23); CDR2 (EIHPDSSTINYAPSLKD, SEQ ID NO: 24); and CDR3 (LYFGFPWFAY, SEQ ID NO: 25) and human framework region sequences and an IgG1 human constant region, wherein administration of the naked hMN-14 antibody to a cancer expressing CEA sensitizes the cancer to administration of an apoptosis agent selected from the group consisting of DTIC and CPT-11; and

b) an apoptosis agent selected from the group consisting of DTIC and CPT-11, wherein the combination of the naked hMN-14 antibody and the apoptosis agent is more effective for treatment of human medullary thyroid carcinoma or human colorectal cancer than either the naked anti-CEA MAb or the apoptosis agent alone or the sum of the effects of the naked anti-CEA MAb and the apoptosis agent administered individually.

114. (Currently amended) A composition comprising:

a) at least one naked humanized, chimeric or human IgG1 Class III anti-CEA MAb that binds to the same epitope of CEA as a murine MN-14 antibody comprising light chain variable region CDR sequences CDR1 (KASQDVGTSA, SEQ ID NO: 20); CDR2 (WTSTRHT, SEQ ID NO: 21); and CDR3 (QQYSLYRS, SEQ ID NO: 22); and heavy chain variable region CDR sequences CDR1 (TYWMS, SEQ ID NO: 23); CDR2 (EIHPDSSTINYAPSLKD, SEQ ID NO: 24); and CDR3 (LYFGFPWFAY, SEQ ID NO: 25), wherein the epitope of CEA is CD66(e); and

b) ~~at least one~~ apoptosis agent selected from the group consisting of DTIC and CPT-11 for treatment of cancer, wherein;

(i) administration of the naked IgG1 Class III anti-CEA antibody to a cancer expressing CEA sensitizes the cancer to the apoptosis agent; and

(ii) the combination of the naked anti-CEA MAb and ~~the apoptosis agent DTIC or CPT-11~~ is more effective for treatment of human medullary thyroid carcinoma or human colorectal cancer than either the naked anti-CEA MAb or ~~the apoptosis agent DTIC or CPT-11~~ alone or the sum of the effects of the naked anti-CEA MAb and ~~the apoptosis agent DTIC or CPT-11~~ administered individually.

115. (New) The composition of claim 111, wherein the apoptosis agent is 5-fluorouracil/leucovorin.